Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments (the eServices portal) close on Thursday 26 January at 4:30pm because of system upgrades. We expect to open them again on Friday 27 January at 8am the latest.

A novel, safe and resistance-free treatment of vaginal candida infections

Reference number
Coordinator GEDEA BIOTECH AB
Funding from Vinnova SEK 1 000 000
Project duration November 2017 - June 2018
Status Completed
Venture Innovative Startups

Purpose and goal

The goal of the project - to further develop the formulation of the selected vaginal tablet prototype, verify its safety in biological tests, and analyse technical stability - has been achieved. Furthermore, the product value chain has been validated through interviews with pharmacy chains, wholesalers and distributors. The company is now preparing to apply for a clinical trial, which is the next milestone.

Expected results and effects

The aim of the project was to further develop the formulation, produce vaginal tablets for analysis of 1 and 3 month technical stability, evaluate biological safety and validate the value chain for the product. The result shows that the blister pack selected for the clinical batches meets the requirements for stability and that the vaginal tablet does not show any signs of irritation or sensitisation in biological tests. Information about stakeholder requirements, costs and time plans has been obtained in the value chain work.

Planned approach and implementation

The selected vaginal tablet prototype from the phase I project has been further developed in collaboration with Galenica AB. A final composition has been selected, manufactured and analyzed for stability in two different blister packs. A final blister pack has been selected based on stability data. Biological tests of the final vaginal tablet have been conducted in cooperation with Eurofins Medical Device Testing and the safety of vaginal tablets has been validated. The project has thus been implemented in accordance with the project outline.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 29 April 2019

Reference number 2017-04519

Page statistics